SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 2%) / Sitagliptin Formulation

Version 4.9   Revision Date: 27.08.2021   SDS Number: 599440-00015   Date of last issue: 09.04.2021
Date of first issue: 04.04.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Ertugliflozin (< 2%) / Sitagliptin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: MSD
Piercetown
A86 HD21 Dunboyne, Ireland

Telephone: 908-740-4000

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Skin irritation, Category 2  H315: Causes skin irritation.
Eye irritation, Category 2  H319: Causes serious eye irritation.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms:

Signal word: Warning

Hazard statements:
H315  Causes skin irritation.
H319  Causes serious eye irritation.

Precautionary statements:
Prevention:
P264  Wash skin thoroughly after handling.
P280  Wear protective gloves/ eye protection/ face protection.

Response:
P332 + P313  If skin irritation occurs: Get medical advice/
2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 30 - &lt; 50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 STOT RE 2; H373 (Kidney, Stomach, Prostate)</td>
<td>&gt;= 1 - &lt; 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
Risks: Causes skin irritation. Causes serious eye irritation.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides
Oxides of phosphorus
5.3 Advice for firefighters

Special protective equipment for firefighters

: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods

: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions

: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions

: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up

: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures

: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 2%) / Sitagliptin Formulation

Version 4.9  Revision Date: 27.08.2021  SDS Number: 599440-00015  Date of last issue: 09.04.2021
Date of first issue: 04.04.2016

Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>TWA</td>
<td>0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>OELV - 8 hrs (TWA)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>OELV - 8 hrs (TWA)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

**Engineering measures**
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

**Personal protective equipment**

Eye protection
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
- Material: Chemical-resistant gloves
- Remarks: Consider double gloving.

Skin and body protection
- Material: Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Equipment should conform to I.S. EN 143
  - Filter type: Particulates type (P)

**SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

- **Physical state**: powder
- **Colour**: No data available
- **Odour**: No data available
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure: Inhalation, Skin contact, Ingestion, Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Sitagliptin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Ertugliflozin:
Acute oral toxicity: LD50 (Rat): 500 mg/kg

Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

Skin corrosion/irritation
Causes skin irritation.

Components:

Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Ertugliflozin:
Result: Corrosive
Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: Irritating to eyes.

Ertugliflozin:
Result: Severe irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Sitagliptin:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Method: OECD Test Guideline 429
Result: Not a skin sensitizer.

Ertugliflozin:
Test Type: Local lymph node assay (LLNA)
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Sitagliptin:
Genotoxicity in vitro:
Test Type: Ames test
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 2%) / Sitagliptin Formulation

Genotoxicity in vivo: 
Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Ertugliflozin:
Genotoxicity in vitro: 
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosome aberration test in vitro
Result: negative
Genotoxicity in vivo: 
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Sitagliptin:
Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative
Species: Rat
Application Route: oral (drinking water)
Exposure time: 2 Years
Result: positive
Target Organs: Liver
Remarks: Significant toxicity observed in testing
Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Ertugliflozin:
Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative
Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative
Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen
Reproductive toxicity
Not classified based on available information.

**Components:**

**Sitagliptin:**
Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL Parent: 1,000 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Teratogenicity: LOAEL: 250 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected, No teratogenic effects

**Ertugliflozin:**
Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 250 mg/kg body weight  
Remarks: Maternal toxicity observed.  
No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 200 mg/kg body weight  
Remarks: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 250 mg/kg body weight  
Remarks: No significant adverse effects were reported

**STOT - single exposure**
Not classified based on available information.
STOT - repeated exposure
Not classified based on available information.

Components:

Ertugliflozin:
- Exposure routes: Oral
- Target Organs: Kidney, Stomach, Prostate
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sitagliptin:
- Species: Mouse
  - NOAEL: 500 mg/kg
  - LOAEL: 1,000 mg/kg
- Application Route: Oral
- Exposure time: > 2 yr
- Target Organs: Kidney

Species: Rat
- NOAEL: 500 mg/kg
- LOAEL: 1,000 mg/kg
- Application Route: Oral
- Exposure time: 14 Weeks
- Target Organs: Liver, Kidney, Heart, Teeth

Species: Dog
- NOAEL: 10 mg/kg
- LOAEL: 50 mg/kg
- Application Route: Oral
- Exposure time: 53 Weeks
- Target Organs: Central nervous system
- Symptoms: Loss of balance
- Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Dog
- NOAEL: 2 mg/kg
- LOAEL: 10 mg/kg
- Application Route: Oral
- Exposure time: 27 Weeks
- Target Organs: Skeletal muscle, Central nervous system
- Symptoms: Loss of balance
- Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Monkey
- NOAEL: 100 mg/kg
- Application Route: Oral
- Exposure time: 14 Weeks
Remarks : No significant adverse effects were reported

**Ertugliflozin:**
Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d
Target Organs : Kidney, Bone, Stomach

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone
Remarks : No significant adverse effects were reported

**Aspiration toxicity**
Not classified based on available information.

**11.2 Information on other hazards**

**Endocrine disrupting properties**

**Product:**
Assessment : The substance/mixture does not contain components consid-
Experience with human exposure

**Components:**

**Sitagliptin:**
- **Inhalation:** Symptoms: upper respiratory tract infection, pharyngitis, Headache
- **Ingestion:** Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

**Ertugliflozin:**
- **Ingestion:** Symptoms: The most common side effects are: Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

**SECTION 12: Ecological information**

12.1 Toxicity

**Components:**

**Sitagliptin:**
- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): 60 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
- **Toxicity to microorganisms:** EC50: > 150 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
  - NOEC: 150 mg/l Exposure time: 3 h Test Type: Respiration inhibition
## Toxicity to fish (Chronic toxicity)

- **NOEC**: 9.2 mg/l
- **Exposure time**: 33 d
- **Species**: Pimephales promelas (fathead minnow)
- **Method**: OECD Test Guideline 210

## Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

- **NOEC**: 9.8 mg/l
- **Exposure time**: 21 d
- **Species**: Daphnia magna (Water flea)
- **Method**: OECD Test Guideline 211

### Ertugliflozin:

#### Toxicity to algae/aquatic plants

- **EC50**: Pseudokirchneriella subcapitata (green algae): 77 mg/l
- **Exposure time**: 72 h
- **Method**: OECD Test Guideline 201

- **NOEC**: Pseudokirchneriella subcapitata (green algae): 50 mg/l
- **Exposure time**: 72 h
- **Method**: OECD Test Guideline 201

#### Toxicity to microorganisms

- **EC50**: > 1,000 mg/l
- **Exposure time**: 3 h
- **Test Type**: Respiration inhibition
- **Method**: OECD Test Guideline 209

- **NOEC**: 1,000 mg/l
- **Exposure time**: 3 h
- **Test Type**: Respiration inhibition
- **Method**: OECD Test Guideline 209

#### Toxicity to fish (Chronic toxicity)

- **NOEC**: 1 mg/l
- **Exposure time**: 32 d
- **Species**: Pimephales promelas (fathead minnow)
- **Method**: OECD Test Guideline 210
- **Remarks**: No toxicity at the limit of solubility

#### Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

- **NOEC**: 2.14 mg/l
- **Exposure time**: 21 d
- **Species**: Daphnia magna (Water flea)
- **Method**: OECD Test Guideline 211
- **Remarks**: No toxicity at the limit of solubility

### 12.2 Persistence and degradability

## Components:

### Sotaglptin:

#### Biodegradability

- **Result**: not rapidly degradable
- **Biodegradation**: 39.7 %
- **Exposure time**: 28 d
- **Method**: OECD Test Guideline 314

#### Stability in water

- **pH**: 7
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 2%) / Sitagliptin Formulation

Version 4.9
Revision Date: 27.08.2021
SDS Number: 599440-00015
Date of last issue: 09.04.2021
Date of first issue: 04.04.2016

Hydrolysis: 50 % (401 d)
Method: OECD Test Guideline 111

Ertugliflozin:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 40.8 %
Exposure time: 28 d

12.3 Bioaccumulative potential

Components:
Sitagliptin:
Partition coefficient: n-octanol/water: log Pow: -0.03

Ertugliflozin:
Partition coefficient: n-octanol/water: log Pow: 2.47

12.4 Mobility in soil

Components:
Sitagliptin:
Distribution among environmental compartments: log Koc: 4.37

Ertugliflozin:
Distribution among environmental compartments: log Koc: 2.88

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available
SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H314 : Causes severe skin burns and eye damage.

H318 : Causes serious eye damage.

H319 : Causes serious eye irritation.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Eye Dam. : Serious eye damage

Eye Irrit. : Eye irritation

Skin Corr. : Skin corrosion

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organiza-
SAFETY DATA SHEET
generated according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 2%) / Sitagliptin Formulation

Version: 4.9
Revision Date: 27.08.2021
SDS Number: 599440-00015
Date of last issue: 09.04.2021
Date of first issue: 04.04.2016


Classification of the mixture:
- Skin Irrit. 2: H315, Calculation method
- Eye Irrit. 2: H319, Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN